Treatments for Benign Conditions of the Prostate Gland

  • Bruce R. Kava
  • Jayadev R. Mettu
  • Shivank Bhatia
  • Prasoon P. Mohan
  • Gopal H. Badlani
Chapter

Abstract

Histologically, the prostate is comprised of a network of branched tubuloalveolar glands that are surrounded by a richly innervated, well-vascularized fibromuscular stroma. Benign prostatic hyperplasia (BPH) is often referred to as the most common benign neoplasm in the aging male. It is a distinct histopathologic entity that is characterized by cellular proliferation of both components of the prostate: the glandular and stromal elements. From a clinical standpoint, this may be associated with age-dependent, bothersome, and progressive voiding symptoms.

Keywords

Benign prostatic hyperplasia Prostatic utricular cyst and Mullerian duct cysts Prostatic abscess Mullerian duct cysts Treatment of benign prostate conditions 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    McNeal JE. Pathology of benign prostatic hyperplasia: insight into etiology. Urol Clin N Am. 1990;17:477–86.Google Scholar
  2. 2.
    Lee C, Kozlowski J, Grayhack K. Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate. 1997;31:131–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America Project: benign prostatic hyperplasia. J Urol. 2005;173:1256–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Abrams P. New words for old: lower urinary tract symptoms for "prostatism". BMJ. 1994;308(6934):929–30.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Abrams P. LUTS, BPH, BPE, BPO: a plea for the logical use of correct terms. Rev Urol. 1999;1:65.PubMedCentralPubMedGoogle Scholar
  6. 6.
    McVary KT, Roehrborn CG, et al. American Urological Association Guideline: management of benign prostatic hyperplasia (BPH), revised 2010. J Urol. 2011;185(5):1793–803Google Scholar
  7. 7.
    Reynard J. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol. 2004;14:13.PubMedCrossRefGoogle Scholar
  8. 8.
    Abrams P, Cardozo L, et al. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology. 2003;61:37–49.PubMedCrossRefGoogle Scholar
  9. 9.
    Kupelian V, Wei JT, O’Leary MP, Kuseck JQ, Litman HJ, Link CL, McKinlay JB. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample. Arch Intern Med. 2006;166:2381–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, Chapple CR, Kaplan S, Tubaro A, Aiyer LP, Wein AJ. The prevalence of lower urinary tract symptoms (LUTS) in the USA, The UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104:352–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Barry M, Fowler Jr F, O’Leary M, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549.PubMedGoogle Scholar
  12. 12.
    Barry M, Fowler Jr F, O’Leary M, et al. Measurement Committee of the American Urological Association. Med Care. 1995;22:AS145.Google Scholar
  13. 13.
    Franks LM. Benin nodular hyperplasia of the prostate: a review. Ann R Coll Surg Engl (Lond). 1954;14:92–106.Google Scholar
  14. 14.
    Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9.PubMedGoogle Scholar
  15. 15.
    Oesterling JE, Jacobsen SJ, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA. 1993;270:860–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Roehrborn CG, Fuh V, et al. The relationship between total and free PSA, prostate volume and age in men age 40–60 with no clinical diagnosis of benign prostatic hyperplasia necessitating therapy. J Urol. 2000;163(Suppl):252.Google Scholar
  17. 17.
    Chute CG, Panser LA, Girman CJ, Oesterling JE, Gues HA, Jacobsen SJ, Lieber MM. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150:85–9.PubMedGoogle Scholar
  18. 18.
    Wei JT, Schottenfeld D, Cooper K, Taylor JM, Faerber GJ, Velarde MA, Bree R, Montie JE, Cooney KA. The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate, and bothersomeness. J Urol. 2001;165:1521–5.PubMedCrossRefGoogle Scholar
  19. 19.
    McConnell JD, Roehrborn CG, Bautisa O, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387–98.PubMedCrossRefGoogle Scholar
  20. 20.
    Filson CP, Wei JT, Hollingsworth JM. Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2013;82:1386–93.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol. 2008;10:14–25.PubMedCentralPubMedGoogle Scholar
  22. 22.
    Verhamme KMC, Dielman JP, Bleumink GS, Bosch JLHR, Stricker BHC, Sturkenboom MCJM. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUT suggestive of benign prostatic hyperplasia: the Triumph Project. Eur Urol. 2003;44:539–45.PubMedCrossRefGoogle Scholar
  23. 23.
    Malaeb BS, Yu X, McBean AM, Elliot SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000–2008). Urology. 2012;79(5):1111–6.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’Dow J, Nordling J, de la Rosette JJ. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118–40.PubMedCrossRefGoogle Scholar
  25. 25.
    Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC. Transurethral prostatectomy: immediate and postoperative complications, a cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol. 1989;141:243–7.PubMedGoogle Scholar
  26. 26.
    Doll HA, Black NA, McPherson K, Flood AB, Williams GB, Smith JC. Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol. 1992;147:1566–73.PubMedGoogle Scholar
  27. 27.
    Horninger W, Unterlechner H, Strasser H, Bartsch G. Transurethral prostatectomy: mortality and morbidity. Prostate. 1996;28:195–200.PubMedCrossRefGoogle Scholar
  28. 28.
    Uchida T, Ohori M, Soh S, Sato T, Iwamura M, Ao T, Koshiba K. Factors influencing morbidity in patients undergoing transurethral resection of the prostate. Urology. 1999;53:98–104.PubMedCrossRefGoogle Scholar
  29. 29.
    Berger AP, Wirtenberger W, Bektic J, Steiner H, Spranger R, Bartsch G. Safer transurethral resection of the prostate: coagulating intermittent cutting reduces hemostatic complications. J Urol. 2004;171:289–91.PubMedCrossRefGoogle Scholar
  30. 30.
    Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, Lack N, Stief CG. Morbidity, mortality, and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180:246–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Mamoulakis C, Efthimlou I, Kazoulis S, Christoulakis I, Sofras F. The modified Clavien classification system: a standard platform for reporting complications in transurethral resection of the prostate. World J Urol. 2011;29:205–10.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Madersbacher S, Lackner J, Brossner C, Rohlich M, Stancik I, Willinger M, Schatzl G. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide long-term analysis of 23,123 cases. Eur Urol. 2005;47:499–504.PubMedCrossRefGoogle Scholar
  33. 33.
    Varkarakis J, Bartsch G, Horninger W. Long-term morbidity and mortality of transurethral prostatectomy: a 10-year follow-up. Prostate. 2004;58:248–51.PubMedCrossRefGoogle Scholar
  34. 34.
    Rassweiller J, Schulze M, Stock C, Teber D, de La Rosette J. Bipolar transurethral resection of the prostate- technical modifications and early clinical experience. Minim Invasive Ther Allied Technol. 2007;16:11–21.CrossRefGoogle Scholar
  35. 35.
    Geavlete B, Stanescu F, Iacoboaie C, Geavlete P. Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases- a medium term, prospective, randomized comparison. BJU Int. 2013;111:793–803.PubMedCrossRefGoogle Scholar
  36. 36.
    Cornu J-N, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, McVary K, Novara G, Woo H, Madersbacher S. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015;67(6):1066–96.PubMedCrossRefGoogle Scholar
  37. 37.
    Autorino R, Damiano R, DiLorenzo G, Quarto G, Persona S, D’Armiento M, DeSio M. Four year outcome of a prospective randomized trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. Eur Urol. 2009;55:922–31.PubMedCrossRefGoogle Scholar
  38. 38.
    Chen Q, Zhang L, Fan QL, Zhou J, Peng YB, Wang Z. Bipolar transurethral resection in saline vs traditional monopolar resection of the prostate: results of a randomized trial with a 2-year follow-up. BJU Int. 2010;106:1339–43.PubMedCrossRefGoogle Scholar
  39. 39.
    Geavelete B, Georgescu D, Multescu R, Stanescu F, Jecu M, Geavlete P. Bipolar plasma vaporization vs monopolar and bipolar TURP- a prospective, randomized, long-term comparison. Urology. 2011;78:930–6.CrossRefGoogle Scholar
  40. 40.
    Mamoulakis C, Schulze M, Skolarikos A, Alivizatos G, Scarpa RM, Rassweiler JJ, de la Rosette JJMCH, Scaffone CM. Midterm results from an international multicentre randomized controlled trial comparing bipolar with monopolar transurethral resection of the prostate. Eur Urol. 2013;63:667–76.PubMedCrossRefGoogle Scholar
  41. 41.
    Komura K, Inamoto T, Takai T, Uchimoto T, Saito K, Tanda N, Minami K, Uehara H, Takahara K, Hirano H, Nomi H, Kiyama S, Watsuji T, Azuma H. Could transurethral resection of the prostate using the TURis system take over conventional monopolar transurethral resection of the prostate? A randomized controlled trial and midterm results. Urology. 2014;84:405–11.PubMedCrossRefGoogle Scholar
  42. 42.
    Te AE. The development of laser prostatectomy. BJU Int. 2004;93:262–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Teichmann H-O, Herrmann TR, Bach T. Technical aspects of lasers in urology. World J Urol. 2007;25:221–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Marks AJ, Teichman JMH. Lasers in clinical urology: state of the art and new horizons. World J Urol. 2007;25:227–33.PubMedCrossRefGoogle Scholar
  45. 45.
    Hermann TRW, Liatsikos EN, Nagele U, Traxer O, Merseburger AS. EAU guidelines on laser technologies. Eur Urol. 2012;61:783–95.CrossRefGoogle Scholar
  46. 46.
    Reich O, Bachmann A, Schneede P, Zaak D, Sulser T, Hofstetter A. Experimental comparison of high power (80W) potassium titanyl phosphate laser vaporization and transurethral resection of the prostate. J Urol. 2004;171:2502–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Bachmann A, Schurch L, Ruszat R, Wyler SF, Seifert H-H, Muller A, Lehmann K, Sulser T. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP); a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol. 2005;48:965–72.PubMedCrossRefGoogle Scholar
  48. 48.
    Sulser T, Reich O, Wyler S, Ruszat R, Casella R, Hofstetter A, Bachmann A. Photoselective KTP laser vaporization of the prostate: first experiences with 65 procedures. J Endourol. 2004;18:976–81.PubMedCrossRefGoogle Scholar
  49. 49.
    Malek RS, Barrett DM, Kuntzman RS. High power potassium titanyl phosphate (KTP/532) laser vaporization prostatectomy: 24 hours later. Urology. 1998;51:254–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA, Malek RS. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12 month results from the first United States multicenter prospective trial. J Urol. 2004;172:1404–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Bouchier-Hayes DM, Van Appledorn S, Bugeja P, Crowe H, Challacombe B, Costello AJ. A randomized trial of photoselective vaporization of the prostate using the 80-W potassium-titanyl-phosphate laser vs transurethral prostatectomy, with a 1-year follow-up. BJU Int. 2010;105:964–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70ml: a short-term prospective randomized trial. Urology. 2008;71:247–51.PubMedCrossRefGoogle Scholar
  53. 53.
    Skolarikos A, Papachristou C, Athanasiadis G, Chalikopoulos D, Deliveliotis C, Alivaizatos G. Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80cc. J Endourol. 2008;22:2333–40.PubMedCrossRefGoogle Scholar
  54. 54.
    Lukacs B, Loeffler J, Bruyere F, Blanchet P, Gelet A, Coloby P, De la Taille A, Lemaire P, Baron J-C, Cornu J-N, Aout M, Rousseau H, Vicaut E. Photoselective vaporization of the prostate with GreenLight 120-W laser compared with monopolar transurethral resection of the prostate: a multicenter randomized controlled trial. Eur Urol. 2012;61:1165–73.PubMedCrossRefGoogle Scholar
  55. 55.
    Bachman A, Tubaro A, Barber N, d’Ancona F, Muir G, et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6 month safety and efficacy results of a European multicentre randomized trail – the Goliath Study. Eur Urol. 2014;65:931–42.CrossRefGoogle Scholar
  56. 56.
    Pfitzenmaier J, Gilfrich C, Pritsch M, et al. Vaporization of prostates of > or = 80ml using a potassium-titanyl-phosphate laser: mid-term results and comparison with prostates < 80ml. BJU Int. 2008;102:322–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Al-Ansari A, Younes N, Sampige VP, et al. Greenlight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow –up. Eur Urol. 2010;58:349–55.PubMedCrossRefGoogle Scholar
  58. 58.
    Tasci AI, Tugcu V, Sahin S, Zorluoglu F. Rapid communication photoselective vaporization of the prostate versus transurethral resection of the prostate for the large prostate: a prospective nonrandomized bicenter trial with 2-year follow- up. J Endourol. 2008;22:347–53.PubMedCrossRefGoogle Scholar
  59. 59.
    Thangasamy IA, Chalasani V, Bachmann A, Woo HH. Photoselective vaporisation of the prostate using 80W and 120W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012. Eur Urol. 2012;62:315–23.PubMedCrossRefGoogle Scholar
  60. 60.
    Gilling PJ, Fraundorfer MR. Holmium laser prostatectomy: a technique in evolution. Curr Opin Urol. 1998;8:11–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Motet N, Anidjar M, Bourdon O, et al. Randomized comparison of transurethral electroresection and holmium:YAG laser vaporization for symptomatic benign prostatic hyperplasia. J Endourol. 1999;13:127–30.CrossRefGoogle Scholar
  62. 62.
    Gilling PJ, Kennett KM, Das AK, Thomson D, Fraundorfer MR. Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation: an update on the early clinical experience. J Endourol. 1998;12:457–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Tan AH, Gilling PJ. Holmium laser prostatectomy: current techniques. Urology. 2002;60:152–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Gilling P, Mackey M, Cresswell M, et al. Holmium laser versus transurethral resection of the prostate: a randomized prospective trial with 1-year follow up. J Urol. 1999;162:1640–4.PubMedCrossRefGoogle Scholar
  65. 65.
    Kuntz RM. Laser treatment of benign prostatic hyperplasia. World J Urol. 2007;25:241–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Tan AHH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40–200 grams). J Urol. 2003;170:1270–4.PubMedCrossRefGoogle Scholar
  67. 67.
    Lerner LB, Tyson MD. Holmium laser applications of the prostate. Urol Clin North Am. 2009;36:485–95.PubMedCrossRefGoogle Scholar
  68. 68.
    KuntzRM AS, Lehrich K, Fayad A. Transurethral holmium laser enucleation of the prostate versus transurethral electrocautery resection of the prostate: a randomized prospective trial in 200 patients. J Urol. 2004;172:1012–6.CrossRefGoogle Scholar
  69. 69.
    Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanoni M, Vanlenti S, Vavassori I, Rigatti P. Holmium laser enucleation versus transurethral resection of the prostate: results form a 2-center, prospective randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol. 2004;172(5):1926–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Gupta N, Sivaramakrishna Kumar R, Dogra PN, Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40g. BJU Int. 2006;97:85–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Wilson LC, Gilling PJ, Williams A, Kennett KM, Frampton CM, Westenberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. Eur Urol. 2006;50(3):569–73.PubMedCrossRefGoogle Scholar
  72. 72.
    Sun N, Fu Y, Tian T, Gao J, Wang Y, et al. Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a randomized clinical trial. Int Urol Nephrol. 2014;46:1277–82.PubMedCrossRefGoogle Scholar
  73. 73.
    Ahyai SA, Lehrich K, Kuntz RM. Holmium laser enucleation versus transurethral resection of the prostate: 3 year follow up results of a randomized clinical trial. Eur Urol. 2007;52:1456–63.PubMedCrossRefGoogle Scholar
  74. 74.
    Naspro R, Suardi N, Salonia A, et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70g: 24 month follow- up. Eur Urol. 2006;50:563–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Kuntz RM, Lehrich K. Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100g: a randomized prospective trail of 120 patients. J Urol. 2002;168:1465–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Gilling PJ, Aho TF, Frampton CM, King CJ, Fraundorfer MR. Holmium laser enucleation of the prostate: results at 6 years. Eur Urol. 2008;53:744–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100g: 5 year follow up results of a randomized clinical trial. Eur Urol. 2008;53:160–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Xia S-J, Zhuo J, Sun X-W, Han B-M, Shao Y, Zhang Y-N. Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur Urol. 2008;53:382–90.PubMedCrossRefGoogle Scholar
  79. 79.
    Fu WJ, Zhang X, Yang Y, et al. Comparison of 2 micron continuous wave laser vaporesection of the prostate and transurethral resection of the prostate: a prospective, nonrandomized trial with 1-year follow up. Urology. 2010;75:194–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Shao Q, Zhang FB, Shang DH, Tian Y. Comparison of holmium and thulium laser in transurethral enucleation of the prostate. Zhonghua Nan Ke Xue. 2009;15:346–9 (in Chinese).PubMedGoogle Scholar
  81. 81.
    Bolmsjo M, Wagrell L, Hallin A, Eliasson T, Erlandsson BE, Mattiasson A. The heat is on–but how? A comparison of TUMT devices. Br J Urol. 1996;78(4):564–72.PubMedCrossRefGoogle Scholar
  82. 82.
    Hoffman RM, Monga M, Elliott SP, Macdonald R, Langsjoen J, Tacklind J, Wilt TJ. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;(9):CD004135. doi: 10.1002/14651858.CD004135.pub3.
  83. 83.
    Naslund MJ. Transurethral needle ablation of the prostate. Urology. 1997;50(2):167–72. doi: 10.1016/S0090-4295(97)00277-X.PubMedCrossRefGoogle Scholar
  84. 84.
    Bouza C, Lopez T, Magro A, Navalpotro L, Amate JM. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol. 2006;6:14. doi: 10.1186/1471-2490-6-14.PubMedCentralPubMedCrossRefGoogle Scholar
  85. 85.
    Campo B, Bergamaschi F, Corrada P, Ordesi G. Transurethral needle ablation (TUNA) of the prostate: a clinical and urodynamic evaluation. Urology. 1997;49(6):847–50.PubMedCrossRefGoogle Scholar
  86. 86.
    Steele GS, Sleep DJ. Transurethral needle ablation of the prostate: a urodynamic based study with 2-year followup. J Urol. 1997;158(5):1834–8.PubMedCrossRefGoogle Scholar
  87. 87.
    Murai M, Tachibana M, Miki M, Shiozawa H, Hirao Y, Okajima E. Transurethral needle ablation of the prostate: an initial Japanese clinical trial. Int J Urol. 2001;8(3):99–105.PubMedCrossRefGoogle Scholar
  88. 88.
    Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol. 2003;44(1):89–93.PubMedCrossRefGoogle Scholar
  89. 89.
    Larcher A, Broglia L, Lughezzani G, Mistretta F, Abrate A, Lista G, Fossati N, et al. Urethral lift for benign prostatic hyperplasia: a comprehensive review of the literature. Curr Urol Rep. 2013;14:620–7.PubMedCrossRefGoogle Scholar
  90. 90.
    McNicholas TA, Woo HH, Chin PT, Bolton D, Arjona MF, et al. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol. 2013;64:292–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Roerhborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: The L.I.F.T. Study. J Urol. 2013;190:2161–7.CrossRefGoogle Scholar
  92. 92.
    Woo HH, Bolton DM, Laborde E, Jack G, Chin PT, Rashid P, Thavaseelan J, McVary KT. Preservation of sexual function with the prostatic urethral lift; a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9:568–75.PubMedCrossRefGoogle Scholar
  93. 93.
    Granados EA, Riley G, Salvador J, Vincente J. Prostatic abscess: diagnosis and treatment. J Urol. 1992;148(1):80–2.PubMedGoogle Scholar
  94. 94.
    Collado A, Palou J, Garcia-Penit J, Salvador J, de la Torre P, Vicente J. Ultrasound-guided needle aspiration in prostatic abscess. Urology. 1999;53(3):548–52.PubMedCrossRefGoogle Scholar
  95. 95.
    Vyas JB, Ganpule SA, Ganpule AP, Sabnis RB, Desai MR. Transrectal ultrasound-guided aspiration in the management of prostatic abscess: a single-center experience. Indian J Radiol Imaging. 2013;23(3):253–7.PubMedCentralPubMedCrossRefGoogle Scholar
  96. 96.
    Jang K, Lee DH, Lee SH, Chung BH. Treatment of prostatic abscess: case collection and comparison of treatment methods. Korean J Urol. 2012;53(12):860–4.PubMedCentralPubMedCrossRefGoogle Scholar
  97. 97.
    Bachor R, Gottfried HW, Hautmann R. Minimal invasive therapy of prostatic abscess by transrectal ultrasound-guided perineal drainage. Eur Urol. 1995;28(4):320–4.PubMedGoogle Scholar
  98. 98.
    Trauzzi SJ, Kay CJ, Kaufman DG, Lowe FC. Management of prostatic abscess in patients with human immunodeficiency syndrome. Urology. 1994;43(5):629–33.PubMedCrossRefGoogle Scholar
  99. 99.
    Jacobsen JD, Kvist E. Prostatic abscess. A review of literature and a presentation of 5 cases. Scand J Urol Nephrol. 1993;27(2):281–4.PubMedCrossRefGoogle Scholar
  100. 100.
    Barozzi L, Pavlica P, Menchi I, De Matteis M, Canepari M. Prostatic abscess: diagnosis and treatment. AJR Am J Roentgenol. 1998;170(3):753–7.PubMedCrossRefGoogle Scholar
  101. 101.
    Varkarakis J, Sebe P, Pinggera GM, Bartsch G, Strasser H. Three-dimensional ultrasound guidance for percutaneous drainage of prostatic abscesses. Urology. 2004;63(6):1017–20; discussion 20.PubMedCrossRefGoogle Scholar
  102. 102.
    Lim JW, Ko YT, Lee DH, Park SJ, Oh JH, Yoon Y, et al. Treatment of prostatic abscess: value of transrectal ultrasonographically guided needle aspiration. J Ultrasound Med. 2000;19(9):609–17.PubMedGoogle Scholar
  103. 103.
    Coppens L, Bonnet P, Andrianne R, de Leval J. Adult mullerian duct or utricle cyst: clinical significance and therapeutic management of 65 cases. J Urol. 2002;167(4):1740–4.PubMedCrossRefGoogle Scholar
  104. 104.
    Moukaddam HA, Haddad MC, El-Sayyed K, Wazzan W. Diagnosis and treatment of midline prostatic cysts. Clin Imaging. 2003;27(1):44–6.PubMedCrossRefGoogle Scholar
  105. 105.
    Kim ED, Onel E, Honig SC, Lipschultz LI. The prevalence of cystic abnormalities of the prostate involving the ejaculatory ducts as detected by transrectal ultrasound. Int Urol Nephrol. 1997;29(6):647–52.PubMedCrossRefGoogle Scholar
  106. 106.
    Halpern EJ, Hirsch IH. Sonographically guided transurethral laser incision of a Mullerian duct cyst for treatment of ejaculatory duct obstruction. AJR Am J Roentgenol. 2000;175(3):777.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Bruce R. Kava
    • 1
  • Jayadev R. Mettu
    • 2
  • Shivank Bhatia
    • 3
  • Prasoon P. Mohan
    • 4
  • Gopal H. Badlani
    • 5
  1. 1.Department of UrologyUniversity of Miami Health SystemMiamiUSA
  2. 2.Department of UrologyWake Forest School of MedicineWinston-SalemUSA
  3. 3.Department of RadiologyJackson Memorial Hospital, University of Miami HospitalMiamiUSA
  4. 4.Department of RadiologyUniversity of Miami Miller School of MedicineMiamiUSA
  5. 5.Department of UrologyWake Forest Baptist Medical CenterWinston-SalemUSA

Personalised recommendations